UK markets open in 6 hours 55 minutes

Enanta Pharmaceuticals, Inc. (9EP.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
12.70+0.60 (+4.96%)
At close: 09:55PM CEST
Currency in EUR

Valuation measures4

Market cap (intra-day) 271.18M
Enterprise value -19.68M
Trailing P/E 424.30
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.89
Price/book (mrq)1.50
Enterprise value/revenue -0.27
Enterprise value/EBITDA 0.16

Trading information

Stock price history

Beta (5Y monthly) 0.49
52-week change 3-60.06%
S&P500 52-week change 323.10%
52-week high 333.00
52-week low 37.50
50-day moving average 313.49
200-day moving average 311.45

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 521.16M
Implied shares outstanding 621.35M
Float 813.34M
% held by insiders 16.10%
% held by institutions 1100.17%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 30 Sept 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -187.77%
Operating margin (ttm)-193.78%

Management effectiveness

Return on assets (ttm)-22.89%
Return on equity (ttm)-56.11%

Income statement

Revenue (ttm)73.62M
Revenue per share (ttm)3.50
Quarterly revenue growth (yoy)-23.70%
Gross profit (ttm)N/A
EBITDA -139.58M
Net income avi to common (ttm)-138.24M
Diluted EPS (ttm)-6.13
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)337.15M
Total cash per share (mrq)15.94
Total debt (mrq)215.04M
Total debt/equity (mrq)112.07%
Current ratio (mrq)6.25
Book value per share (mrq)9.07

Cash flow statement

Operating cash flow (ttm)-92.5M
Levered free cash flow (ttm)-51.68M